Treatment of chronic hypercalcemia

Medicinal Chemistry

Volumn 8, Issue 4, 2012, Pages 556-563

  Camozzi, Valentina ^a   Luisetto, Giovanni ^a   Basso, Stefano M M ^b   Cappelletti, Piero ^c   Tozzoli, Renato ^c   Lumachi, Franco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Bisphosphonates; Hypercalcemia; Hyperparathyroidism; Parathyroidectomy; PTHrP; RANKL

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CATHEPSIN K INHIBITOR; CINACALCET; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; FUROSEMIDE; HYDROCORTISONE; IBANDRONIC ACID; ODANACATIB; PAMIDRONIC ACID; PREDNISONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BREAST CANCER; CALCIUM ABSORPTION; CALCIUM EXCRETION; CANCER INVASION; CELLULITIS; CHRONIC DISEASE; DEHYDRATION; DRUG DOSE INCREASE; DRUG MEGADOSE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LASER COAGULATION; NAUSEA; NONHUMAN; OSTEOPOROSIS; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REHYDRATION; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW (TOPIC); VOMITING;

ALGORITHMS; CHRONIC DISEASE; HUMANS; HYPERCALCEMIA;

EID: 84863764384     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340612801216355     Document Type: Article

References (71)

1. Makras, P.; Papapoulos, S. E. Medical treatment of hypercalcaemia. Hormones, 2009, 8, 83-95.
2. Ralston, S. H. Medical management of hypercalcaemia. Br. J Clin. Pharmacol., 1992, 34, 11-20.
3. LeGrand, S. B.; Leskuski, D.; Zama, I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann. Intern. Med., 2008, 149, 259-263.
4. Zaidi, M.; Inzerillo, A. M.; Moonga, B. S.; Bevis, P. J.; Huang, C. L. Forty years of calcitonin - where are we now ? A tribute to the work of Iain Macintyre, FRS. Bone, 2002, 30, 655-663.
5. Pondel, M. Calcitonin and calcitonin receptors: bone and beyond. Int. J. Exp. Pathol., 2000, 81, 405-422.
6. Sharma, O. P. Vitamin D, calcium, and sarcoidosis. Chest, 1996, 109, 535-539.
7. Russell, R. G.; Xia, Z.; Dunford, J. E.; Oppermann, U.; Kwaasi, A.; Hulley, P. A.; Kavanagh, K. L.; Triffitt, J. T.; Lundy, M. W.; Phipps, R. J.; Barnett, B. L.; Coxon, F. P.; Rogers, M. J.; Watts, N. B.; Ebetino, F. H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N. Y. Acad. Sci., 2007, 1117, 209-257.
8. Russell, R. G. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci., 2006, 1068, 367-401.
9. Body, J. J. Current and future directions in medical therapy: hypercalcemia. Cancer, 2000, 88, 3054-3058.
10. Onuma, E.; Azuma, Y.; Saito, H.; Tsunenari T.; Watanabe, T.; Hirabayashi, M.; Sato, K.; Yamada-Okabe, H.; Ogata, E. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin. Cancer Res., 2005, 11, 4198-4203.
11. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell A.; Belch A.; Mackey J.; Apffelstaedt J.; Hussein M. A.; Coleman, R. E.; Reitsma, D. J.; Chen, B. L.; Seaman, J. J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98, 1735-1744.
12. Lipton, A.; Theriault, R. I.; Hortobagil, G. N.; Simeone J.; Knight, R. D.; Mellars, K.; Reitsma D. J.; Heffernan, M.; Seaman, J. J. Pamidronate prevents skeletal complication and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo controlled trials. Cancer, 2000, 88, 1082-1090.
13. Smith, M. R. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat. Rev., 2005, 31, 19-25.
14. Camozzi, V.; Franzin, C.; Luisetto, G. Medical treatment of hypercalcemia. In: Hypercalcemia. Pathophysiology and Treatment, Lumachi, F.; Basso, S. M. M., Eds.; Bentham Science Publishers: Sharjah (U. A. E.), 2009, pp. 88-99.
15. Coleman, R.; Cook, R.; Hirsh, V.; Major, P.; Lipton, A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer. 2011, 117(1), 11-23.
16. Aapro, M.; Abrahamsson, P. A.; Body, J. J.; Coleman, R. E.; Colomer, R.; Costa, L.; Crinò, L.; Dirix, L.; Gnant, M.; Gralow, J.; Hadji, P.; Hortobagyi, G. N.; Jonat, W.; Lipton, A.; Monnier, A.; Paterson, A. H.; Rizzoli, R.; Saad, F.; Thürlimann, B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol., 2008, 19, 420-432.
17. Silverman, S. L.; Landesberg, R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am. J. Med., 2009, 122, S33-S45.
18. Hoff, A. O.; Toth, B. B.; Altundag, K.; Johnson, M. M.; Warneke, C. L.; Hu, M.; Nooka, A.; Sayegh, G.; Guarneri, V.; Desrouleaux, K.; Cui, J.; Adamus, A.; Gagel, R. F.; Hortobagyi, G. N. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res., 2008, 23, 826-836.
19. Wüthrich, R. P.; Martin, D.; Bilezikian, J. P. The role of calcimimetics in the treatment of hyperparathyroidism. Eur. J. Clin. Invest., 2007, 37, 915-922.
20. Khan, A.; Grey, A.; Shoback, D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab., 2009, 94, 373-381.
21. Peacock, M.; Bilezikian, J. P.; Klassen, P. S.; Guo, M. D.; Turner, S. A.; Shoback, D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyper-pathyroidism. J. Clin. Endocrinol. Metab., 2005, 90, 135-141.
22. Collins, M. T.; Skarulis, M. C.; Bilezikian, J. P.; Silverberg, S. J.; Spiegel, A. M.; Marx, S. J.; Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J. Clin. Endocrinol. Metab., 1998, 83, 1083-1088.
23. Lindberg, J. S.; Culleton, B.; Wong, G.; Borah, M. F.; Clark, R. V.; Shapiro, W. B.; Roger, S. D.; Husserl, F. E.; Klassen, P. S.; Guo, M. D.; Albizem, M. B.; Coburn, J. W. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, doubleblind, multicentre study. J. Am. Soc. Nephrol., 2005, 16, 800-807.
24. Kearns, A. E.; Khosla, S.; Kostenuik, P. J. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev., 2008, 29, 155-192.
25. Roodman, G. D.; Dougall, W. C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat. Rev., 2008, 34, 92-101.
26. Clezardin, P.; Teti, A. Bone metastasis: pathogenesis and therapeutic implications. Clin. Exp. Metastasis, 2007, 24, 599-608.
27. Burkiewicz, J. S.; Scarpace, S. L.; Bruce, S. P. Denosumab in osteoporosis and oncology. Ann. Pharmacother., 2009, 43, 1445-1455.
28. Body, J. J.; Facon, T.; Coleman, R. E.; Lipton, A.; Geurs, F.; Fan, M.; Holloway, D.; Peterson, M. C.; Bekker, P. J. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res., 2006, 12, 1221-1228.
29. Crook, M. K.; Guise, T. A. RANKL: Targeting bone and cancer to treat skeletal complications of malignancy. IBMS Bone Key, 2009, 6, 323-338.
30. Body, J. J.; Lipton, A.; Gralow, J. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J. Bone Miner. Res., 2009, 25, 440-446.
31. Stopeck, A. T.; Lipton, A.; Body, J. J.; Steger, G. G.; Tonkin, K.; De Boer, R. H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D. A.; Viniegra, M.; Fan, M.; Jiang, Q.; Dansey, R.; Jun, S.; Braun, A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J. Clin. Oncol., 2010, 28(35), 5132-9.
32. Lumachi, F.; Brunello, A.; Roma, A.; Basso, U. Cancer-induced hypercalcemia. Anticancer Res., 2009, 29, 1551-1555.
33. Onuma, E.; Sato, K.; Saito, H.; Tsunenari, T.; Ishii, K.; Esaki, K.; Yabuta, N.; Wakahara, Y.; Yamada-Okabe, H.; Ogata, E. Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res., 2004, 24, 2665-2673.
34. Iguchi, H.; Aramaki, Y.; Maruta, S.; Takiguchi, S. Effects of antiparathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. J. Bone Miner. Metab., 2006, 24, 16-19.
35. Jensen, A. B.; Wynne, C.; Ramirez, G.; He, W.; Song, Y.; Berd, Y.; Wang, H.; Mehta, A.; Lombardi, A.; The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin. Breast Cancer., 2010, 10, 452-8
36. Le Gall, C.; Bonnelye, E.; Clézardin, P. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support Palliat. Care, 2008, 2(3), 218-22.
37. Hall, C. L.; Keller, E. T. The role of Wnts in bone metastases. Cancer Metastasis Rev., 2006, 25, 551-558.
38. Voorzanger-Rousselot, N.; Journe, F.; Doriath, V.; Body, J. J.; Garnero, P. Assessment of circulating Dickkopf-1 with a new twosite immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int., 2009, 84, 348-354.
39. Shoback, D. D.; Marcus, R. Mineral metabolism & metabolic disease. In: Basic & Clinical Endocrinology, Greenspan, F. S.; Gardner, D. G., Eds.; McGraw-Hill: New York, 2001, pp. 237-333.
40. Triponez, F.; Clark, O. H.; Vanrenthergem, Y.; Evenepoel, P. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann. Surg., 2008, 248, 18-30.
41. Pitt, S. C.; Sippel, R. S.; Chen, H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg. Clin. North Am., 2009, 89, 1227-1239.
42. Lumachi, F.; Brunello, A.; Roma, A.; Basso, U. Medical treatment of malignancy-associated hypercalcemia. Curr. Med. Chem., 2008, 15, 415-421.
43. Grill, V.; Martin, T. J. Hypercalcemia of malignancy. Rev. Endocr. Metabol. Dis., 2000, 1, 253-263.
44. Iglesias, P.; Díez, J. J. Current treatments in the management of patients with primary hyperparathyroidism. Postgrad. Med. J., 2009, 85, 15-23.
45. Udelsman, R.; Pasieka, J. L.; Sturgeon, C.; Young, J. E. M.; Clark, O. H. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J. Clin. Endocrinol. Metab., 2009, 94, 366-372.
46. Bilezikian, J. P.; Khan, A. A.; Potts, J. T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J. Clin. Endocrinol. Metab., 2009, 94, 335-339.
47. Basso, S. M. M.; Lumachi, F. Surgical treatment of hypercalcemia. In: Hypercalcemia. Pathophysiology & treatment, Lumachi, F.; Basso, S. M. M., Eds.; Bentham Science Publishers: Sharjah (U. A. E.), 2009; pp. 76-87.
48. Kouvaraki, M. A.; Greer, M.; Sharma, S.; Berry, D.; Armand, R.; Lee, J. E.; Evans, D. B.; Perrier, N. D. Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery, 2006, 139, 527-534.
49. Lumachi, F.; Ermani, M.; Basso, S. M.; Camozzi, V.; Nardi, A.; Luisetto, G. Short-and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif. Tissue Int., 2003, 73, 44-48.
50. Lumachi, F.; Camozzi, V.; Ermani, M.; Nardi, A.; Luisetto. G. Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender. Ann. N. Y. Acad. Sci., 2007, 1117, 362-366.
51. Fraser, W. D. Hyperparathyroidism. Lancet, 2009, 374, 145-158.
52. Caillard, C.; Sebag, F.; Mathonnet, M.; Gibelin, H.; Brunaud, L.; Loudot, C.; Kraimps, J. L.; Hamy, A.; Bresler, L.; Charbonnel, B.; Leborgne, J.; Henry, J. F.; Nguyen, J. M.; Mirallié, E. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year followup). Surgery, 2007, 141, 153-159.
53. Morris, G. S.; Grubbs, E. G.; Hearon, C. M.; Gantela, S.; Lee, J. E.; Evans, D. B.; Holmes, H. M.; Busaidy, N. L.; Jimenez, C.; Perrier, N. D. Parathyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparathyroidism: a randomized control trial. Ann. Surg., 2010, 251, 832-837.
54. Rubin, M. R.; Bilezikian, J. P.; McMahon, D. J.; Jacobs, T.; Shane, E.; Siris, E.; Udesky, J.; Silverberg, S. J. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metabol., 2008, 93, 3462-3470.
55. Lew, J.; Solorzano, C. C. Surgical management of primary hyperparathyroidism: state of the art. Surg. Clin. North Am., 2009, 89, 1205-1225.
56. Low, R. A.; Katz, A. D. Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases. Head Neck, 1998, 20, 583-587.
57. Wang, C.-A. Surgery of the parathyroid glands. Adv. Surg., 1971, 5, 105-127.
58. Tibblin, S., Bondeson, A.-G.; Ljungberg, O. Unilateral parathyroidectomy in hyperpara-thyroidism due to single adenoma. Ann. Surg., 1982, 195, 245-252.
59. Sackett, W. R.; Barraclough, B.; Reeve, T. S.; Delbridge, L. W. Worldwide trends in the surgical treatment of primary hyperpara thyroidism in the era of minimally invasive parathyroidectomy. Arch. Surg., 2002, 137, 1055-1059.
60. Sebag, F.; Hubbard, J. G.; Maweja, S.; Misso, C.; Tardivet, L.; Henry, J. F. Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism. Surgery, 2003, 134, 1038-1041.
61. Lumachi, F.; Zucchetta, P.; Marzola, M. C.; Boccagni, P.; Angelini, F.; Bui, F.; D'Amico, D. F. Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: comparative study in 91 patients with primary hyperparathyroidism. Eur. J. Endocrinol., 2000, 143, 755-760.
62. Lumachi, F.; Ermani, M.; Basso, S. M. M.; Zucchetta, P.; Borsato, N. Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocr. Relat. Cancer, 2001, 8, 63-69.
63. Chien, D.; Jacene, H. Imaging of Parathyroid Glands. Otolaryngol. Clin. North Am., 2010, 43, 399-415.
64. Patel, C. N.; Salahudeen, H. M.; Lansdownb, M.; Scarsbrook, A. F. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin. Radiol., 2010, 65, 278-287.
65. Udelsman, R. Six hundred fifty six consecutive explorations for primary hyperparathyroidism. Ann. Surg., 2002, 235, 665-672.
66. Miccoli, P.; Berti, P.; Materazzi, G.; Massi, M.; Picone, A.; Minuto, M. N. Results of video-assisted parathyroidectomy: single institution's six-year experience. World J. Surg., 2004, 28, 1216-1218.
67. Lumachi, F.; Marzola, M. C.; Zucchetta, P.; Cecchin, D.; Bui, F. Different operative protocols for minimally invasive radioguided parathyroidectomy. A randomized prospective study. Ann. Surg. Oncol., 2004, 11, S103-S104.
68. Ikeda, Y.; Takayama, J.; Takami. H. Minimally invasive radioguided parathyroidectomy for hyperparathyroidism. Ann. Nucl. Med., 2010, 24, 233-240.
69. Lumachi, F.; Basso, S. M.; Basso, U. Parathyroid cancer. Etiology, clinical presentation and treatment. Anticancer Res., 2006, 26, 4804-4808.
70. Busaidy, N. L.; Jimenez, C.; Habra, M. A.; Schultz, P. N.; El-Naggar, A. K.; Clayman, G. L.; Asper, J. A.; Diaz, E. M. Jr.; Evans, D. B.; Gagel, R. F.; Garden, A.; Hoff, A. O.; Lee, J. E.; Morrison, W. H.; Rosenthal, D. I.; Sherman, S. I.; Sturgis, E. M.; Waguespack, S. G.; Weber, R. S.; Wirfel, K.; Vassilopoulou-Sellin, R. Parathyroid carcinoma: a 22-year experience. Head Neck, 2004, 26, 716-726.
71. Okamoto, T.; Iihara, M.; Obara, T.; Tsukada, T. Parathyroid carcinoma: etiology, clinical presentation and treatment. World J. Surg., 2009, 33, 2343-2354.